査読有
doi：10.1016/j.ejca.2026.116750
PubMed No.：42068971
2024 Impact Factor：7.1
種類：原著
誌名：European Journal of Cancer
発行年月：2026年4月
巻号頁：240: 116750, 2026
論題：Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab
著者：Andrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Mario Scartozzi, Emiliano Tamburini, Francesco Giuseppe Foschi, Silvia Camera, Mara Persano, Alessandra Pia D'Agata, Michele Ferrara, Laura Passeri, Lorenza Rimassa, Margherita Rimini
